Abbott Laboratories Dossier
Qualitative Analysis
Business overview
Abbott Laboratories is a leading global healthcare company that develops, manufactures, and sells a highly diversified portfolio of healthcare products. The company operates across four primary business segments: Medical Devices, Diagnostic Products, Nutritional Products, and Established Pharmaceuticals. Abbott's Medical Devices segment is a major growth engine, featuring market-leading products in continuous glucose monitoring (the FreeStyle Libre portfolio), electrophysiology, rhythm management, structural heart, and heart failure. The Diagnostics segment provides laboratory, rapid, molecular, and point-of-care testing systems, and has recently been expanded to include a dedicated Cancer Diagnostics business following the strategic acquisition of Exact Sciences. The Nutritional Products segment offers pediatric and adult nutrition brands such as Ensure and Glucerna, while the Established Pharmaceuticals segment provides branded generic medicines in key emerging markets across Latin America, Asia-Pacific, and other regions.
Research as of 29 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Acquisition and integration of Exact Sciences Corporation to establish a leading position in the fast-growing cancer screening and precision oncology diagnostics segments.
Expected impact: Establishes a new growth vertical, adding market-leading tests like Cologuard and Oncotype DX, and doubling the addressable market of Abbott's diagnostics unit.
Construction of a new state-of-the-art cardiovascular device manufacturing facility in Georgia to support growing global demand for electrophysiology, heart failure, and structural heart devices.
Expected impact: Significantly increases production capacity for high-growth medical devices and strengthens supply chain resilience.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Enables Abbott to enter and lead in the fast-growing cancer screening, precision oncology, and genetic testing segments. The acquisition adds a powerful new platform (including Cologuard and Oncotype DX) to Abbott's diagnostics portfolio, doubling its total addressable market.
Financial impact: Expected to add approximately $3 billion of incremental sales in 2026, accelerate Abbott's 2026 sales growth by approximately 0.5%, and dilute 2026 adjusted EPS by approximately $0.20.
Strategic Partnerships
Abbott will incorporate ALZpath's proprietary phosphorylated Tau 217 (pTau217) antibody into the development of an in vitro diagnostic (IVD) blood test for Alzheimer's disease on Abbott's Alinity ci-series immunoassay systems, accelerating the adoption of scalable, blood-based brain health diagnostics.
Terms: Financial terms of the licensing agreement were not disclosed.